Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nucryst Pharmaceuticals, a developer of medical products for infection and inflammation, has appointed Drew Fitch to its board of directors.
Subscribe to our email newsletter
Mr Fitch is the president and CEO of The Westaim Corporation, Nucryst’s controlling shareholder, holding approximately 75% of Nucryst’s outstanding common shares. Prior to his appointment as president and CEO of Westaim in 2007, Mr Fitch had been senior vice president and CFO of Westaim since 1997.
Before joining Westaim, Mr Fitch was senior vice president and CFO of Western Star Trucks Holdings., a manufacturer of city transit buses and highway trucks, and senior vice president of finance and CFO of Canadian Airlines, an international airline company.
Thomas Gardner, chairman of Nucryst, said: “The addition of Drew Fitch to the Nucryst board of directors adds a seasoned director and will help us to coordinate our priorities with Westaim. On behalf of the board, we extend to Drew a warm welcome.”